Peng Hao, Yao Meng, Fan Hongwei, Song Liwei, Sun Jinwen, Zhou Zheng, Du Yunfeng, Lu Keyu, Li Tao, Yin Aiguo, Xu Jianhua, Wei Shidong
Department of General Surgery, Beijing Meitan General Hospital , Beijing, China .
Cancer Biother Radiopharm. 2017 Aug;32(6):221-226. doi: 10.1089/cbr.2017.2246.
To evaluate the efficacy and safety of postoperative adjuvant immunotherapy with cytokine-induced killer (CIK) cells in combination with chemotherapy (CT) in colorectal cancer (CRC) patients.
A total of 46 patients were randomly assigned to either group 1 (control group) or group 2 (CIK group) using blocked randomization. Both groups received the FOLFOX4 (5-fluorouridine, leucovorin, and oxaliplatin) CT. In the CIK group, patients were given CIK cell infusion after FOLFOX4 CT. Treatment efficacy, adverse effects, and quality of life (QOL) were assessed.
During the first 2 years of follow-up, the recurrence rate in the CIK group (26.1%, 6 in 23 cases) was significantly lower than the control group (43.5%, 10 in 23). The survival time was significantly longer in the CIK group (41.9 months, 95% confidence interval [CI]: 38.2-45.7) than in the control group (33.8 months, 95% CI: 28.4-39.2). Although QOL was reduced in both treatment groups, adjuvant CIK cell transfusion significantly improved the QOL in patients with CRC. Toxicity was mild in patients with CIK treatment.
Immunotherapy with CIK cells may serve as an adjuvant treatment in patients with CRC after CT with prolonged survival of patients, limited side-effects, and improved QOL.
评估细胞因子诱导的杀伤细胞（CIK）联合化疗（CT）对结直肠癌（CRC）患者进行术后辅助免疫治疗的疗效和安全性。
采用区组随机化方法将46例患者随机分为1组（对照组）和2组（CIK组）。两组均接受FOLFOX4（5-氟尿苷、亚叶酸钙和奥沙利铂）化疗。在CIK组，患者在接受FOLFOX4化疗后进行CIK细胞输注。评估治疗效果、不良反应和生活质量（QOL）。
在随访的前2年中，CIK组的复发率（26.1%，23例中有6例）显著低于对照组（43.5%，23例中有10例）。CIK组的生存时间（41.9个月，95%置信区间[CI]：38.2 - 45.7）显著长于对照组（33.8个月，95% CI：28.4 - 39.2）。虽然两个治疗组的生活质量均有所下降，但辅助CIK细胞输注显著改善了CRC患者的生活质量。CIK治疗患者的毒性较轻。
CIK细胞免疫治疗可作为CRC患者CT后的辅助治疗，可延长患者生存期，副作用有限，并改善生活质量。
